Assembly Biosciences (NASDAQ:ASMB) Shares Down 6.3% – What’s Next?

Assembly Biosciences, Inc. (NASDAQ:ASMB) shares dropped 6.3% during mid-day trading on Thursday . The company traded as low as $31.02 and last traded at $30.80. 80,476 shares traded hands during trading, a decline of 52% from the average session volume of 167,561 shares. The stock had previously closed at $32.87.

Analyst Upgrades and Downgrades

ASMB has been the topic of a number of research reports. Mizuho set a $53.00 target price on shares of Assembly Biosciences in a research report on Tuesday, September 1st. Wall Street Zen cut Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a research note on Tuesday, August 18th. Finally, Guggenheim reiterated a “buy” rating and issued a $43.00 target price on shares of Assembly Biosciences in a report on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $45.60.

Assembly Biosciences Price Performance

The stock’s fifty day simple moving average is $29.68 and its 200-day simple moving average is $28.36. The firm has a market cap of $632.99 million, a PE ratio of 30.48 and a beta of 1.13.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.52. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%.The business had revenue of $13.37 million for the quarter, compared to the consensus estimate of $8.60 million. Analysts expect that Assembly Biosciences, Inc. will post 2.28 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Bank of America Corp DE lifted its holdings in shares of Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 3,319 shares during the period. California State Teachers Retirement System acquired a new stake in shares of Assembly Biosciences during the 2nd quarter worth approximately $103,000. Seven Fleet Capital Management LP purchased a new position in shares of Assembly Biosciences during the 4th quarter valued at approximately $147,000. Acadian Asset Management LLC lifted its stake in shares of Assembly Biosciences by 42.1% in the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 6,823 shares during the period. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Assembly Biosciences in the fourth quarter worth about $228,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.